KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Halozyme Therapeutics (HALO) FCF Margin (2016 - 2025)

Historic FCF Margin for Halozyme Therapeutics (HALO) over the last 16 years, with Q3 2025 value amounting to 49.56%.

  • Halozyme Therapeutics' FCF Margin rose 103100.0% to 49.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 48.47%, marking a year-over-year increase of 70200.0%. This contributed to the annual value of 46.13% for FY2024, which is 11200.0% up from last year.
  • Halozyme Therapeutics' FCF Margin amounted to 49.56% in Q3 2025, which was up 103100.0% from 30.13% recorded in Q2 2025.
  • Halozyme Therapeutics' FCF Margin's 5-year high stood at 104.67% during Q3 2021, with a 5-year trough of 23.0% in Q2 2024.
  • Moreover, its 5-year median value for FCF Margin was 43.37% (2023), whereas its average is 48.6%.
  • In the last 5 years, Halozyme Therapeutics' FCF Margin soared by 956300bps in 2021 and then tumbled by -718300bps in 2022.
  • Over the past 5 years, Halozyme Therapeutics' FCF Margin (Quarter) stood at 80.74% in 2021, then crashed by -46bps to 43.36% in 2022, then rose by 0bps to 43.37% in 2023, then soared by 36bps to 58.86% in 2024, then fell by -16bps to 49.56% in 2025.
  • Its FCF Margin was 49.56% in Q3 2025, compared to 30.13% in Q2 2025 and 57.87% in Q1 2025.